Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023;57(2):90-99.
doi: 10.1159/000528962. Epub 2023 Jan 9.

Racial and Ethnic Differences in Timing of Diagnosis and Clinical Services Received in Duchenne Muscular Dystrophy

Affiliations

Racial and Ethnic Differences in Timing of Diagnosis and Clinical Services Received in Duchenne Muscular Dystrophy

Joshua R Mann et al. Neuroepidemiology. 2023.

Abstract

Introduction: Racial/ethnic differences in diagnostic and treatment services have been identified for a range of health conditions and outcomes. The current study aimed to analyze whether there are racial/ethnic differences in the timing of diagnostic testing and treatments for males with Duchenne muscular dystrophy (DMD).

Methods: Diagnostic and clinical data for male individuals with DMD born during 1990-2010 were analyzed from eight sites (Arizona, Colorado, Georgia, Iowa, Piedmont Region of North Carolina, Western New York, South Carolina, and Utah) of the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet). Seven milestones related to diagnosis/treatment experiences were selected as outcomes. Times to each milestone were estimated and compared by four racial/ethnic groups using Kaplan-Meier estimation and Cox proportional-hazards models. Times between initial evaluation or diagnostic testing and later milestones were also compared by race/ethnicity.

Results: We identified 682 males with definite or probable DMD of whom 61.7% were non-Hispanic white, 20.5% Hispanic, 10.6% other, and 7.2% non-Hispanic black. Seven milestone events were studied (initial evaluation, first neurology/neuromuscular visit, diagnosis, corticosteroid treatment first offered, corticosteroid treatment started, first electrocardiogram or echocardiogram, and first pulmonary function test). The first five milestone events occurred at an older age for non-Hispanic black individuals compared to non-Hispanic white individuals. Time to first offering of corticosteroids and initiation of corticosteroid therapy was later for Hispanic individuals compared to non-Hispanic white individuals. When accounting for timing of initial evaluation/diagnosis, offering of corticosteroids continued to occur later, but first pulmonary testing occurred earlier, among Hispanic individuals compared to non-Hispanic whites. No significant delays remained for non-Hispanic black individuals after accounting for later initial evaluation/diagnosis.

Conclusion: We described racial/ethnic differences in ages at selected diagnostic and treatment milestones. The most notable differences were significant delays for five of seven milestones in non-Hispanic black individuals, which appeared to be attributable to later initial evaluation/diagnosis. Findings for Hispanic individuals were less consistent. Efforts to address barriers to early evaluation and diagnosis for non-Hispanic black children with DMD may promote more timely initiation of recommended disease monitoring and interventions.

Keywords: Disparities; Duchenne muscular dystrophy; Ethnicity; Health services; Race.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

Fig. 1
Fig. 1
Flowchart of study eligibility from eight Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet) sites.
Fig. 2
Fig. 2
Timeline map of ages (standard deviations) at seven selected milestones for males with definite or probable DMD, the MD STARnet, N = 682. The hinge represents the mean age; the lower and upper hinges are one standard deviation from the mean; the upper and lower whisker goes from minimum to maximum age. The initial evaluation age and genetic testing could be less than zero due to prenatal testing based on positive family history. Individuals who did not experience the milestone or those who experienced the milestone but the age was not available are excluded from the estimates.
Fig. 3
Fig. 3
Plot of time-dependent aHRs estimated from time-dependent Cox PH modeling for age at first offering of corticosteroids by race/ethnicity among males with definite or probable DMD, the MD STARnet, N = 554. The reference group is non-Hispanic white. aHRs for non-Hispanic black and Hispanic were statistically significant (type I error = 0.05). Age in years at each milestone was used as the survival time; the last medical provider visit was used for those who did not experience the milestone. Individuals who experienced the milestone but the age at the milestone was unavailable were excluded. aHR below 1 indicates a delay for a specific milestone.

References

    1. Yiu EM, Kornberg AJ. Duchenne muscular dystrophy. J Paediatr Child Health. 2015;51((8)):759–764. - PubMed
    1. Mah JK, Korngut L, Fiest KM, Dykeman J, Day LJ, Pringsheim T, et al. A systematic review and meta-analysis on the epidemiology of the muscular dystrophies. Can J Neurol Sci. 2016;43((1)):163–177. - PubMed
    1. Mercuri E, Bönnemann CG, Muntoni F. Muscular dystrophies. Lancet. 2019;394((10213)):2025–2038. - PubMed
    1. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9((1)):77–93. - PubMed
    1. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol. 2010;9((2)):177–189. - PubMed

Publication types

Substances